Enhabit, Inc. EHAB
We take great care to ensure that the data presented and summarized in this overview for Enhabit, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding EHAB
View all-
Black Rock Inc. New York, NY7.69MShares$59.2 Million0.0% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY5MShares$38.5 Million0.73% of portfolio
-
8 Knots Management, LLC Dallas, TX3.81MShares$29.3 Million4.1% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.98MShares$22.9 Million0.0% of portfolio
-
Jana Partners LLC New York, NY2.47MShares$19.1 Million2.13% of portfolio
-
Arex Capital Management, LP New York, NY2.44MShares$18.8 Million22.98% of portfolio
-
Systematic Financial Management LP Teaneck, NJ1.84MShares$14.2 Million0.38% of portfolio
-
Dimensional Fund Advisors LP Austin, TX1.74MShares$13.4 Million0.0% of portfolio
-
Ubs Group Ag1.68MShares$13 Million0.0% of portfolio
-
Paradice Investment Management LLC1.58MShares$12.2 Million2.21% of portfolio
Latest Institutional Activity in EHAB
Top Purchases
Top Sells
About EHAB
Enhabit, Inc. provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services. The company also offers hospice services, including pain and symptom management, palliative and dietary counseling, social worker visits, spiritual counseling, and bereavement counseling services to meet the individual physical, emotional, spiritual, and psychosocial needs of terminally ill patients and their families. As of March 31, 2022, it operated in 252 home health agencies and 99 hospice agencies across 34 states. The company was formerly known as Encompass Health Home Health Holdings, Inc. and changed its name to Enhabit, Inc. in March 2022. Enhabit, Inc. was incorporated in 2014 and is headquartered in Dallas, Texas. As of July 1, 2022, Enhabit, Inc. operates as a standalone company.
Insider Transactions at EHAB
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Jan 10
2025
|
Mark W Ohlendorf Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,404
+10.92%
|
$16,828
$7.8 P/Share
|
Jan 10
2025
|
Charles M Elson Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,404
+4.23%
|
$16,828
$7.8 P/Share
|
Jan 10
2025
|
Stuart M Mcguigan Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,404
+4.66%
|
$16,828
$7.8 P/Share
|
Jan 10
2025
|
Barry P. Schochet Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,045
+6.63%
|
$21,315
$7.8 P/Share
|
Jan 10
2025
|
Gregory S Rush Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,205
+5.96%
|
$22,435
$7.8 P/Share
|
Jan 10
2025
|
Erin Hoeflinger Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,045
+5.6%
|
$21,315
$7.8 P/Share
|
Jan 10
2025
|
Jeffrey Bolton Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,808
+4.46%
|
$33,656
$7.8 P/Share
|
Jan 01
2025
|
Julie Diane Jolley EVP of Home Health Operations |
SELL
Payment of exercise price or tax liability
|
Direct |
3,458
-2.5%
|
$24,206
$7.81 P/Share
|
Jan 01
2025
|
Barbara Ann Jacobsmeyer President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
16,834
-1.8%
|
$117,838
$7.81 P/Share
|
Jan 01
2025
|
Ronald Leroy Langham Jr EVP Clinical Excel. & Strategy |
SELL
Payment of exercise price or tax liability
|
Direct |
1,687
-1.5%
|
$11,809
$7.81 P/Share
|
Jan 01
2025
|
Tanya Renee Marion Chief Human Resources Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,800
-2.13%
|
$12,600
$7.81 P/Share
|
Dec 12
2024
|
Jeffrey Bolton Director |
BUY
Open market or private purchase
|
Direct |
4,000
+3.92%
|
$32,000
$8.69 P/Share
|
Dec 10
2024
|
Stuart M Mcguigan Director |
BUY
Open market or private purchase
|
Direct |
15,000
+24.27%
|
$120,000
$8.81 P/Share
|
Nov 12
2024
|
Jeffrey Bolton Director |
BUY
Open market or private purchase
|
Direct |
3,000
+3.09%
|
$21,000
$7.6 P/Share
|
Nov 08
2024
|
Jeffrey Bolton Director |
BUY
Open market or private purchase
|
Direct |
7,000
+3.64%
|
$49,000
$7.76 P/Share
|
Oct 10
2024
|
Mark W Ohlendorf Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,633
+13.27%
|
$18,431
$7.12 P/Share
|
Oct 10
2024
|
Barry P. Schochet Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,336
+7.73%
|
$23,352
$7.12 P/Share
|
Oct 10
2024
|
Gregory S Rush Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,511
+6.9%
|
$24,577
$7.12 P/Share
|
Oct 10
2024
|
Erin Hoeflinger Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,336
+6.46%
|
$23,352
$7.12 P/Share
|
Oct 10
2024
|
Charles M Elson Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,633
+4.82%
|
$18,431
$7.12 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 349K shares |
---|---|
Open market or private purchase | 63K shares |
Payment of exercise price or tax liability | 45.2K shares |
---|---|
Open market or private sale | 634 shares |